BioSpace News Archive

Gamida Cell Reports Second Quarter and First Half 2023 Financial Results and Provides Company Update.

Venatorx Pharmaceuticals today highlights two recent publications that provide important updates on the changing epidemiology of carbapenem-resistant Enterobacterales (CRE) globally and in the United States (US).

Antibe Therapeutics Inc. has filed its financial and operating results for the fiscal quarter ended June 30, 2023.

Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Sigilon Therapeutics, Inc. (NASDAQ: SGTX).

Zura Bio Limited today announced its financial results for the second quarter ended June 30, 2023, and recent business highlights.

Gracell Biotechnologies Inc. today reported second quarter unaudited financial results for the period ended June 30, 2023, and provided corporate updates.

Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced pipeline progress and business updates and reported financial results for the second quarter ended June 30, 2023.

POINT Biopharma Global Inc. today announced financial results for the second quarter ended June 30, 2023, and provided a business update.

Harmony Biosciences Holdings, Inc. (“Harmony”) (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced a definitive agreement to acquire Zynerba Pharmaceuticals, Inc.

Catalyst Pharmaceuticals, Inc. today announced that multiple abstracts highlighting FYCOMPA ® (perampanel) CIII will be presented at the upcoming 35th International Epilepsy Congress (“IEC”) taking place on September 2 – 6, 2023.